ArriVent BioPharma, Inc. Balance Sheet
AVBP / Health Care|2 years of annual SEC 10-K data (FY2023-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 2 fiscal years. All figures from audited SEC 10-K filings.
ArriVent BioPharma, Inc. had $275M in total assets and $258M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| Cash & Equivalents | $74.3M | $150.4M |
| Current Assets | $227.0M | $160.0M |
| Total Assets | $274.9M | $163.1M |
| Current Liabilities | $17.3M | $11.6M |
| Shareholders' Equity | $257.7M | -$153.2M |